Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methyl aminolevulinate - Galderma

X
Drug Profile

Methyl aminolevulinate - Galderma

Alternative Names: 5-ALA methylester; 5-ALA-methylesther; Aminolevulinic acid methyl ester; CD06809-41; Luxerm; MAL-PDT; Methyl 5 aminolevulinate; Methylaminolevulinate; Metvix; Metvix Natural Daylight Photodynamic Therapy - Galderma; Metvix NDL-PDT; Metvix PDT; Metvixia; P 1202; Visonac

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian Radium Hospital; PhotoCure
  • Developer Galderma; Healthcare Logistics; Photocure
  • Class Amino acids; Antineoplastics; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Squamous cell cancer
  • Phase II Acne
  • Discontinued Skin aging

Most Recent Events

  • 04 Jan 2024 No development reported - Phase-III for Actinic keratosis in Puerto Rico (Topical) (Galderma website; January 2024)
  • 01 Sep 2021 Galderma terminates a phase III trial for Actinic keratosis in USA and Puerto Rico due to sponsor's decision (Topical) (NCT04269395)
  • 04 Mar 2021 Galderma completes a phase III trial in Actinic keratosis in Puerto Rico and USA (Topical) (NCT04085367)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top